Company Description
Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated ocular and systemic diseases.
The company's lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases and allergic conjunctivitis.
It also develops ADX-629, a first-in-class orally administered RASP modulator that is Phase II clinical trial for psoriasis, asthma, and COVID-19; and ADX-2191, a dihydrofolate reductase inhibitor which is in phase 3 for the prevention of proliferative vitreoretinopathy, and phase II clinical trial for the treatment of retinitis pigmentosa, as well as for treating primary vitreoretinal lymphoma.
The company has a license agreement with Madrigal Pharmaceuticals, Inc. for developing ADX-1612, which inhibits the protein chaperome for the treatment of inflammatory diseases.
The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014.
Aldeyra Therapeutics, Inc. was incorporated in 2004 and is based in Lexington, Massachusetts.
Country | United States |
IPO Date | May 2, 2014 |
Industry | Biotechnology |
Sector | Healthcare |
Employees | 9 |
CEO | Dr. Todd C. Brady M.D., Ph.D. |
Contact Details
Address: 131 Hartwell Avenue Lexington, Massachusetts United States | |
Website | https://www.aldeyra.com |
Stock Details
Ticker Symbol | ALDX |
Exchange | NASDAQ |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0001341235 |
CUSIP Number | 01438T106 |
ISIN Number | US01438T1060 |
Employer ID | 00-0000000 |
SIC Code | 2834 |
Key Executives
Name | Position |
---|---|
Dr. Todd C. Brady M.D., Ph.D. | Chief Executive Officer, President & Director |
David Burke | Head of Investor Relations |
Dr. Stephen G. Machatha Ph.D. | Chief Development Officer |
Laura Nichols | Operations Manager |
Michael Alfieri | Principal Financial & Accounting Officer |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Nov 18, 2024 | 8-K | Current Report |
Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
Nov 07, 2024 | 10-Q | Quarterly Report |
Oct 21, 2024 | 4 | Filing |
Oct 03, 2024 | 8-K | Current Report |
Oct 02, 2024 | 8-K | Current Report |
Sep 10, 2024 | 3 | Filing |
Sep 03, 2024 | 8-K | Current Report |
Aug 14, 2024 | 4 | Filing |
Aug 14, 2024 | 4 | Filing |